LEADER 02779nam 2200541 450 001 9910793648903321 005 20230715102610.0 010 $a0-253-04265-8 010 $a0-253-04263-1 035 $a(CKB)4100000008421899 035 $a(OCoLC)1096214652 035 $a(MdBmJHUP)muse86409 035 $a(MiAaPQ)EBC5789192 035 $a(Au-PeEL)EBL5789192 035 $a(MiAaPQ)EBC30356849 035 $a(Au-PeEL)EBL30356849 035 $a(EXLCZ)994100000008421899 100 $a20230715d2019 uy 0 101 0 $aeng 135 $aur|||||||nn|n 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFrom Pugwash to Putin $ea critical history of US-Soviet scientific cooperation /$fGerson S. Sher 205 $a1st ed. 210 1$aBloomington, Indiana :$cIndiana University Press,$d[2019] 210 4$d©2019 215 $a1 online resource (xiii, 306 pages) $cillustration ; 311 $a0-253-04262-3 311 $a0-253-04261-5 320 $aIncludes bibliographical references and index. 327 $aCover -- Title Page -- Copyright -- Dedication -- Contents -- Acknowledgments -- Introduction -- Part I: The Timeline -- 1. The Deep Cold War and the Exchange Programs -- 2. De?tente and the Heyday of Massive Agreements -- 3. Sanctions and Perestroika -- 4. After the Fall: New Times, New Approaches -- Part II: In Their Own Words -- 5. How Did It Start? -- 6. What Kept Them Going? -- 7. Scientific Accomplishments -- 8. Other Accomplishments -- 9. Problems -- 10. On the Nature of Science in the Former Soviet Union -- 11. Vignettes -- Part III: Conclusion: So What? -- 12. What to Make of It All? -- Appendix: List of Interviews -- Bibliography -- Index -- About the Author. 330 $a"For 60 years, scientists from the United States and the Soviet Union participated in state-organized programs of collaboration. From the first scientific exchanges of the Cold War years through the fall of the Soviet Union, Gerson S. Sher, a former manager of these cooperative programs, provides a detailed and critical assessment of what worked, what didn't, and why it matters"--$cProvided by publisher. 606 $aScience$xInternational cooperation 606 $aTechnology$xInternational cooperation 607 $aUnited States$xRelations$zRussia (Federation) 607 $aRussia (Federation)$xRelations$zUnited States 615 0$aScience$xInternational cooperation. 615 0$aTechnology$xInternational cooperation. 676 $a338.926 700 $aSher$b Gerson S.$f1947-$01139385 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910793648903321 996 $aFrom Pugwash to Putin$93853076 997 $aUNINA LEADER 01193nam a2200229 i 4500 001 991004313635107536 005 20240423135405.0 008 240409s1891 it r 001 0 ita d 040 $aBibl. Interfacoltà T. Pellegrino$bita$cSocioculturale Scs 041 0 $aita 082 04$a346.4508221$223 110 2 $aItalia$kLeggi$0423419 245 10$aSui servizi della Cassa Depositi e Prestiti e Casse di risparmio postali in rapporto alle leggi civile, commerciale, penale, dei lavori pubblici, dell'espropriazione per pubblica utilità ed amministrative /$ccommento dell'avvocato Paolo Clementini 260 $aTorino :$bUnione tipografico-editrice,$c1891 300 $a2 volumi ; 24 cm 505 00$gVol. 1. -$g542 p. 505 00$gVol.2. -$g546-1039 p. 650 4$aCasse di risparmio$xLegislazione$zItalia$yEd. ante 1900 700 1 $aClementini, Paolo$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0226792 912 $a991004313635107536 996 $aSui servizi della Cassa Depositi e Prestiti e Casse di risparmio postali in rapporto alle leggi civile, commerciale, penale, dei lavori pubblici, dell'espropriazione per pubblica utilità ed amministrative$94148762 997 $aUNISALENTO LEADER 06995nam 22013213u 450 001 9910808713803321 005 20251116164038.0 010 $a1-283-20363-4 010 $a9786613203632 010 $a0-470-92935-9 010 $a0-470-92934-0 035 $a(CKB)2550000000042753 035 $a(EBL)818637 035 $a(OCoLC)746598445 035 $a(SSID)ssj0000534041 035 $a(PQKBManifestationID)12165841 035 $a(PQKBTitleCode)TC0000534041 035 $a(PQKBWorkID)10493413 035 $a(PQKB)10894419 035 $a(MiAaPQ)EBC818637 035 $a(PPN)190360267 035 $a(EXLCZ)992550000000042753 100 $a20131230d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntiviral Drugs $eFrom Basic Discovery Through Clinical Trials 205 $a1st ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (470 p.) 300 $aDescription based upon print version of record. 311 08$a1-118-25122-9 311 08$a0-470-45563-2 327 $aANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients 327 $a7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 327 $a14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 327 $a21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 327 $a29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate 330 $aThis book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so 606 $aAntiviral Agents -- therapeutic use 606 $aAntiviral agents 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aDrug Evaluation 606 $aAntiviral agents 606 $aEpidemiologic Studies 606 $aChemistry, Pharmaceutical 606 $aEvaluation Studies as Topic 606 $aInvestigative Techniques 606 $aAnti-Infective Agents 606 $aEpidemiologic Methods 606 $aPharmacology 606 $aTherapeutic Uses 606 $aHealth Care Evaluation Mechanisms 606 $aChemistry 606 $aBiological Science Disciplines 606 $aNatural Science Disciplines 606 $aQuality of Health Care 606 $aPublic Health 606 $aPharmacologic Actions 606 $aEnvironment and Public Health 606 $aHealth Care Quality, Access, and Evaluation 606 $aChemical Actions and Uses 606 $aDelivery of Health Care 606 $aClinical Trials as Topic 606 $aDrug Discovery 606 $aAntiviral Agents 606 $aDrug Evaluation 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 4$aAntiviral Agents -- therapeutic use. 615 4$aAntiviral agents. 615 4$aClinical Trials as Topic. 615 4$aDrug Discovery. 615 4$aDrug Evaluation. 615 0$aAntiviral agents. 615 2$aEpidemiologic Studies. 615 2$aChemistry, Pharmaceutical. 615 2$aEvaluation Studies as Topic. 615 2$aInvestigative Techniques. 615 2$aAnti-Infective Agents. 615 2$aEpidemiologic Methods. 615 2$aPharmacology. 615 2$aTherapeutic Uses. 615 2$aHealth Care Evaluation Mechanisms. 615 2$aChemistry. 615 2$aBiological Science Disciplines. 615 2$aNatural Science Disciplines. 615 2$aQuality of Health Care. 615 2$aPublic Health. 615 2$aPharmacologic Actions. 615 2$aEnvironment and Public Health. 615 2$aHealth Care Quality, Access, and Evaluation. 615 2$aChemical Actions and Uses. 615 2$aDelivery of Health Care. 615 2$aClinical Trials as Topic. 615 2$aDrug Discovery. 615 2$aAntiviral Agents. 615 2$aDrug Evaluation. 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.7924 700 $aKazmierski$b Wieslaw M$01671234 702 $aKazmierski$b Wieslaw M. 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910808713803321 996 $aAntiviral Drugs$94033635 997 $aUNINA